New antibody drugs are showing results in pancreatic cancer, a disease area that has been regarded as an incurable disease. Recently, a new bispecific antibody drug from the Dutch company Merus was approved for the treatment of pancreatic cancer in the United States. In clinical trials, the drug has shown therapeutic effects in patients with pancreatic cancer and non-small cell lung cancer.

In Korea, efforts to develop new antibody drugs for pancreatic cancer are also underway. Prestige BioPharma, Aptamer Sciences, and ABL Bio have confirmed the potential of antibody drugs in pancreatic cancer.

Merus’s HER2·HER3 targeted bispecific antibody secures indications for pancreatic cancer and